The role of inflammation in HPV carcinogenesis

Carcinogenesis

Volumn 31, Issue 11, 2010, Pages 1905-1912

  Boccardo, Enrique ^a,b   Lepique, Ana P ^a,b   Villa, Luisa L ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA INTERFERON; BETA DEFENSIN; BETA INTERFERON; CATHELICIDIN ANTIMICROBIAL PEPTIDE 18; CYCLIN A; CYCLIN B; DIOXYGENASE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE; INDOLEAMINE 2, 3 DIOXYGENASE; INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; ONCOPROTEIN; PACLITAXEL; POLYPEPTIDE ANTIBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CANCER RISK; CARCINOGENESIS; CHLAMYDIA TRACHOMATIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DNA DAMAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; MUTAGENESIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVICITIS; UTERINE CERVIX CANCER; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; NEOPLASMS; ONCOGENES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 78149246312     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq176     Document Type: Review

References (116)

1. Aggarwal, B.B. et al. (2006) Inflammation and cancer: how hot is the link? Biochem. Pharmacol., 72, 1605-1621.
2. Balkwill, F. et al. (2004) Cancer: an inflammatory link. Nature, 431, 405-406
3. Bosch, F.X. et al. (2007) The epidemiology of human papillomavirus infection and cervical cancer. Dis. Markers, 23, 213-227.
4. zur Hausen, H. (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2, 342-350.
5. Frazer, I.H. (2009) Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology, 384, 410-414.
6. Scott, M. et al. (2001) Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol., 8, 209-220.
7. Stanley, M.A. et al. (2007) HPV: from infection to cancer. Biochem. Soc. Trans., 35, 1456-1460.
8. IARC Working Group. (2007) Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Vol. 90, International Agency for Research on Cancer, Lyon.
9. Howley, P.M. et al. (2007) Papillomaviruses. Lippincot Williams & Wilkins, Philadelphia, PA.
10. Bosch, F.X. et al. (2008) Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26, K1-K16.
11. Francis, D.A. et al. (2000) Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J. Virol., 74, 2679-2686.
12. Goodwin, E.C. et al. (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl Acad. Sci. USA, 97, 12513-12518.
13. Münger, K. et al. (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol., 63, 4417-4421.
14. Halbert, C.L. et al. (1991) The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol., 65, 473-478.
15. McMurray, H.R. et al. (2001) Biology of human papillomavirus. Int. J. Exp. Path., 82, 15-33.
16. Howie, H.L. et al. (2009) Papillomavirus E6 proteins. Virology, 384, 324-334
17. McLaughlin-Drubin, M.E. et al. (2009) The human papillomavirus E7 oncoprotein. Virology, 384, 335-344.
18. Kawai, T. et al. (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol., 21, 317-337.
19. Hasan, U.A. et al. (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol., 178, 3186-3197.
20. Libra, M. et al. (2009) Uterine cervical carcinoma: role of matrix metalloproteinases. Int. J. Oncol., 34, 897-903.
21. Palefsky, J.M. et al. (2003) Chapter 6: immunosuppression and co-infection with HIV. J. Natl Cancer Inst. Monogr., 31, 41-46.
22. Delvenne, P. et al. (1995) Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon-gamma and tumor necrosis factor-alpha. Am. J. Pathol., 146, 589-598.
23. Kim, K.Y. et al. (2000) The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol., 81(Pt 3), 695-700.
24. Um, S.J. et al. (2000) Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int. J. Cancer, 85, 416-423.
25. Kyo, S. et al. (1994) Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology, 200, 130-139.
26. Vieira, K.B. et al. (1996) Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. Cancer Res., 56, 2452-2457.
27. Villa, L.L. et al. (1992) Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18. Mol. Carcinog., 6, 5-9.
28. Schlecht, N.F. et al. (2001) Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA, 286, 3106-3114.
29. Balkwill, F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
30. Tindle, R.W. (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer, 2, 59-65.
31. Chang, Y.E. et al. (2002) Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol., 76, 8864-8874.
32. Herdman, M.T. et al. (2006) Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis, 27, 2341-2353.
33. Turek, L.P. et al. (1982) Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirustransformed mouse cells. Proc. Natl Acad. Sci. USA., 79, 7914-7918.
34. Pett, M.R. et al. (2004) Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res., 64, 1359-1368.
35. Woodworth, C.D. et al. (1992) Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirusimmortalized human cervical cells. Cancer Res., 52, 456-463.
36. Scott, M.E. et al. (2009) Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int. J. Cancer, 124, 1379-1383.
37. Pao, C.C. et al. (1995) Differential expression of cytokine genes in cervical cancer tissues. Biochem. Biophys. Res. Commun., 214, 1146-1151.
38. Schneider, A. et al. (1987) Interferon treatment of human genital papillomavirus infection: importance of viral type. Int. J. Cancer, 40, 610-614.
39. Arany, I. et al. (1995) Interferon resistance is independent from copy numbers in benign HPV-induced lesions. Anticancer Res., 15, 1003-1006.
40. Chang, Y.E. et al. (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol., 74, 4174-4182.
41. Wan, F. et al. (2008) Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int. J. Cancer, 123, 32-40.
42. Barnard, P. et al. (1999) The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology, 259, 305-313.
43. Barnard, P. et al. (2000) The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology, 277, 411-419.
44. Cordano, P. et al. (2008) The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology, 377, 408-418.
45. Nees, M. et al. (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferationassociated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol., 75, 4283-4296.
46. Ronco, L.V. et al. (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev., 12, 2061-2072.
47. Park, J.S. et al. (2000) Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem., 275, 6764-6769.
48. Um, S.J. et al. (2002) Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett., 179, 205-212.
49. Boccardo, E. et al. (2010) Expression of human papillomavirus type 16 E7 oncoprotein alters keratinocytes expression profile in response to tumor necrosis factor-alpha. Carcinogenesis, 31, 521-531.
50. Lace, M.J. et al. (2010) Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes. Virology, 399, 270-279.
51. Dell'oste, V. et al. (2008) Altered expression of UVB-induced cytokines in human papillomavirus-immortalized epithelial cells. J. Gen. Virol., 89, 2461-2466.
52. Rincon-Orozco, B. et al. (2009) Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res., 69, 8718-8725.
53. Pett, M.R. et al. (2006) Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc. Natl Acad. Sci. USA, 103, 3822-3827.
54. Lace, M.J. et al. (2009) Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. Carcinogenesis, 30, 1336-1344.
55. Ota, K. et al. (2010) Interferon-alpha2b induces p21cip1/waf1 degradation and cell proliferation in HeLa cells. Cell Cycle, 9, 131-139.
56. Gröne, A. (2002) Keratinocytes and cytokines. Vet. Immunol. Immunopathol., 88, 1-12.
57. Locksley, R.M. et al. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501.
58. Hehlgans, T. et al. (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology, 115, 1-20.
59. Basile, J.R. et al. (2001) The cytokines tumor necrosis factor-alpha (TNFalpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J. Biol. Chem., 276, 22522-22528.
60. Basile, J.R. et al. (2003) NF-kappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol. Cancer Res., 1, 262-270.
61. Boccardo, E. et al. (2004) HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes. Virology, 328, 233-243.
62. Hagari, Y. et al. (1995) Association of tumor necrosis factor-alpha gene expression and apoptotic cell death with regression of Shope papillomas. J. Invest. Dermatol., 104, 526-529.
63. Termini, L. et al. (2008) Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatment. BMC Med. Genomics, 1, 29.
64. Rösl, F. et al. (1994) Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J. Virol., 68, 2142-2150.
65. Soto, U. et al. (1999) Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene, 18, 3187-3198.
66. Malejczyk, J. et al. (1994) Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-alpha-mediated growth limitation. Int. J. Cancer, 56, 593-598.
67. Duerksen-Hughes, P.J. et al. (1999) HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology, 264, 55-65.
68. Filippova, M. et al. (2005) The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: effect of dose. Cell Death Differ., 12, 1622-1635.
69. James, M.A. et al. (2006) Human papillomavirus type 16 E6 activates NFkappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol., 80, 5301-5307.
70. Balkwill, F. (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev., 13, 135-141.
71. Woodworth, C.D. et al. (1995) Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinomaderived cervical epithelial cells. Proc. Natl Acad. Sci. USA, 92, 2840-2844.
72. Gaiotti, D. et al. (2000) Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinog., 27, 97-109.
73. Ruhland, A. et al. (2001) Opposite regulation of the HPV 20-URR and HPV 27-URR promoters by ultraviolet irradiation and cytokines. Int. J. Cancer, 91, 828-834.
74. Pietenpol, J.A. et al. (1990) TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 61, 777-785.
75. Woodworth, C.D. et al. (1990) Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J. Virol., 64, 4767-4775.
76. Nees, M. et al. (2000) Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res., 60, 4289-4298.
77. Deng, W. et al. (2008) Transforming growth factor beta1 promotes chromosomal instability in human papillomavirus 16 E6E7-infected cervical epithelial cells. Cancer Res., 68, 7200-7209.
78. Zhou, L. et al. (2009) Transcriptional regulatory networks in Th17 cell differentiation. Curr. Opin. Immunol., 21, 146-152.
79. Tartour, E. et al. (1994) Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res., 54, 6243-6248.
80. Castrilli, G. et al. (1997) Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br. J. Cancer, 75, 855-859.
81. Hess, S. et al. (2000) Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production. J. Immunol., 165, 1939-1948.
82. Kleine-Lowinski, K. et al. (2003) Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int. J. Cancer, 107, 407-415.
83. Woodworth, C.D. et al. (1993) Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am. J. Pathol., 142, 1544-1555.
84. De Andrea, M. et al. (2007) Alpha- and betapapillomavirus E6/E7 genes differentially modulate pro-inflammatory gene expression. Virus Res., 124, 220-225.
85. Akgül, B. et al. (2010) Human papillomavirus 5 and 8 E6 downregulate interleukin-8 secretion in primary human keratinocytes. J. Gen. Virol., 91, 888-892.
86. Lai, Y. et al. (2009) AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol., 30, 131-141.
87. Buck, C.B. et al. (2006) Human alpha-defensins block papillomavirus infection. Proc. Natl Acad. Sci. USA, 103, 1516-1521.
88. Quayle, A.J. et al. (1998) Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am. J. Pathol., 152, 1247-1258.
89. Hubert, P. et al. (2007) Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J., 21, 2765-2775.
90. Hubert, P. et al. (2001) Dendritic cells induce the death of human papillomavirus-transformed keratinocytes. FASEB J., 15, 2521-2523.
91. Le Poole, I.C. et al. (2008) Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol. Immunother., 57, 789-797.
92. Kreuter, A. et al. (2009) Human papillomavirus-associated induction of human beta-defensins in anal intraepithelial neoplasia. Br. J. Dermatol., 160, 1197-1205.
93. Conner, K. et al. (2002) The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J. Am. Acad. Dermatol., 47, 347-350.
94. Hammes, L.S. et al. (2007) Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation. Gynecol. Oncol., 105, 157-165.
95. Kobayashi, A. et al. (2008) Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol., 1, 412-420.
96. Mazibrada, J. et al. (2008) Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol., 108, 112-120.
97. Gabrilovich, D.I. et al. (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol., 166, 5398-5406.
98. Lepique, A.P. et al. (2009) HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin. Cancer Res., 15, 4391-4400.
99. Pahler, J.C. et al. (2008) Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia, 10, 329-340.
100. Giraudo, E. et al. (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest., 114, 623-633.
101. de Visser, K.E. et al. (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell, 7, 411-423.
102. Hiraku, Y. et al. (2007) Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection. Cancer Sci., 98, 964-972.
103. Wei, L. et al. (2009) Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirusinfected cells. Cancer Res., 69, 4878-4884.
104. Leong, C.M. et al. (2010) Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections. J. Invest. Dermatol., 130, 472-480.
105. Matthews, K. et al. (2003) Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J. Virol., 77, 8378-8385.
106. Fausch, S.C. et al. (2002) Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol., 169, 3242-3249.
107. Fausch, S.C. et al. (2005) Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J. Immunol., 174, 7172-7178.
108. Mellor, A. (2005) Indoleamine 2, 3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun., 338, 20-24.
109. Moscicki, A.B. et al. (2006) Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine, 24 (suppl. 3), S3/42-S51.
110. Trottier, H. et al. (2006) The epidemiology of genital human papillomavirus infection. Vaccine, 24 (suppl. 1), S1-S15.
111. Castle, P.E. et al. (2003) Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. J. Natl Cancer Inst. Monogr., 31, 29-34.
112. Anttila, T. et al. (2001) Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA, 285, 47-51.
113. Smith, J.S. et al. (2002) Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J. Infect. Dis., 185, 324-331.
114. Smith, J.S. et al. (2002) Herpes simplex virus-2 as a human papillomavirus cofactor in the the etiology of invasive cervical cancer. J. Natl Cancer Inst., 94, 1604-1613.
115. Castle, P.E. et al. (2001) An association of cervical inflammation with highgrade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol. Biomarkers Prev., 10, 1021-1027.
116. Rasmussen, S.J. et al. (1997) Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J. Clin. Invest., 99, 77-87.